Research Notice: All peptides sold by The Peptide Store are intended for laboratory research purposes only. They are not for human consumption, not approved by the FDA, and not intended to diagnose, treat, cure, or prevent any disease.
Research summary: PT-141 (bremelanotide) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH) that acts as a non-selective agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R, with primary studied activity through central MC4R activation. Derived from Melanotan II, it progressed through clinical trials and received FDA approval in 2019 as Vyleesi, giving it both preclinical and clinical data. Sold for laboratory research use only.
PT-141 (bremelanotide) is a synthetic peptide analogue of alpha-melanocyte stimulating hormone (α-MSH) that has progressed through clinical trials and received FDA approval in 2019 as Vyleesi — making it one of the more thoroughly documented peptides in the research literature with both preclinical and clinical data available.
Mechanism: Melanocortin Receptors
PT-141 is a cyclic heptapeptide that acts as a non-selective agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R. Its primary studied activity has been through MC4R activation in the central nervous system — a central mechanism that distinguishes it from peripherally-acting compounds in related categories.
Development History
PT-141 was developed from Melanotan II (MT-II), itself synthesized in the 1980s by Victor Hruby’s peptide chemistry laboratory at the University of Arizona. PT-141 emerged as a specific candidate with a distinct pharmacological profile, subsequently developed through clinical trials by Palatin Technologies.
Clinical Research Data
Phase 2 and Phase 3 clinical trial data has been published in peer-reviewed journals including the Journal of Sexual Medicine, giving researchers access to a relatively robust clinical dataset compared to most research peptides. These trials established the compound’s pharmacokinetic profile and adverse event data in human subjects.
Adverse Effects in Clinical Studies
Clinical studies documented nausea as the most common adverse effect. Flushing and headache were also noted. Blood pressure effects observed with early intranasal administration led to the preference for subcutaneous delivery in later research protocols.